ANI PHARMACEUTICALS, INC Net Income (Loss) Attributable to Parent, Diluted
ANI PHARMACEUTICALS, INC (ANIP) reported Net Income (Loss) Attributable to Parent, Diluted of -$2.36 million for the 3-month period ending 2014-06-30, per its 10-Q filed 2014-08-07.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2014-08-07
- ANI PHARMACEUTICALS, INC net income (loss) attributable to parent, diluted for the quarter ending 2014-06-30 was -$2.36M.
- ANI PHARMACEUTICALS, INC net income (loss) attributable to parent, diluted for the quarter ending 2014-03-31 was $3.36M.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 6 month |
|---|---|---|
| 2014-06-30 | -$2.36M 10-Q · filed 2014-08-07 | $996.00K 10-Q · filed 2014-08-07 |
| 2014-03-31 | $3.36M 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |